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Atherosclerosis is the leading pathological contributor to cardiovascular morbidity and mortality worldwide. As its complex
pathogenesis has been gradually unwoven, the regime of treatments and therapies has increased with still much ground to cover.
Active research in the past decade has attempted to develop antiatherosclerosis vaccines with some positive results. Nevertheless, it
remains to develop a vaccine against atherosclerosis with high aﬃnity, speciﬁcity, eﬃciency, and minimal undesirable pathology.
In this review, we explore vaccine development against atherosclerosis by interpolating a number of novel ﬁndings in the ﬁelds
of vascular biology, immunology, and bioinformatics. With recent technological breakthroughs, vaccine development aﬀords
precision in specifying the nature of the desired immune response—useful when addressing a disease as complex as atherosclerosis
with a manifold of inﬂammatory and autoimmune components. Moreover, our exploration of available bioinformatic tools for
epitope-based vaccine design provides a method to avoid expenditure of excess time or resources.
1.Introduction
Atherosclerosis and its pursuant complications are the lead-
ing causes of death worldwide. Its complex inﬂammatory
and autoimmune pathogenesis has recently provided much
insight for treatment and therapy. The suspicion of a role
for the immune system in atherosclerosis began with the
discovery that atherosclerotic plaques contain cellular and
molecular mediators of innate and adaptive immunity [1–4].
Studies with cytokine gene knockout mice further conﬁrmed
the role of inﬂammation in mediating the innate response
involved in atherosclerosis [5–8]. Moreover, experiments
identifying a role for T-cells in atherogenesis indicate
adaptive immune and potential autoimmune mechanisms
[9–12]. Despite a myriad of available treatments for an ever-
increasing list of targets and risk factors, it remains to ﬁnd
eﬀective treatments with the potential for not only ther-
apeutic but also prophylactic anti-atherosclerotic beneﬁts.
Success of vaccination campaigns against infectious diseases
has demonstrated the proof-of-principle that identiﬁcation
of antigens and pathologically associated immune responses
makes vaccination an attractive therapeutic option. While
the idea of a vaccine against atherosclerosis has a seem-
ingly mythic origin, the demonstrated inﬂammatory and
autoimmune components of atherosclerosis provide a con-
vincing rationale to investigate such a vaccine. Vaccines
have the potential to induce and/or enhance protective
immuneresponsesgeneratedbyantigenswithoutpathogenic
consequences. In fact, active investigation during the past
decade has led to clinical trials for anti-atherosclerosis
vaccines with some positive results. Nevertheless, it remains
todevelopavaccineagainstatherosclerosiswithhighaﬃnity,
speciﬁcity, eﬃciency, and minimal undesirable pathology.
This eﬀort can potentially consume excessive time and
resources. However, a great boon to this ﬁeld is the wealth
of bioinformatic tools available to design such vaccines. In
this brief review, our aim is to summarize the most recent
developments in designing vaccines against atherosclerosis
withafocusonhowtoapplyavarietyofusefulbioinformatic
tools and approaches.2 Journal of Biomedicine and Biotechnology
2. Risk Factors for Atherosclerosis
Atherosclerosis is an inﬂammatory disease characterized by
endothelial activation and dysfunction, lipid accumulation,
monocyte inﬁltration and diﬀerentiation, T-cell inﬁltration
and activation, foam cell formation, and ﬁbrosis in the
lesion area. Two of its common ﬁnal results, coronary
and cerebrovascular disease, are the major causes of mor-
bidity worldwide. Nowadays, atherosclerosis is increasingly
considered an immune-mediated inﬂammatory process of
the vasculature in which intense immunological activity
is occurring. Hypertension, hyperlipidemia, hyperglycemia,
diabetes, obesity, cigarette smoking, age, and sex are well-
established risk factors for atherosclerosis [13, 14]. Recent
research from our team and others’ laboratories has also
identiﬁedhyperhomocysteinemiaasanindependentriskfac-
tor for atherosclerosis [15–17]. However, these well-deﬁned
risk factors do not account for all incidences of the disease.
Infectiousdisease, suchasChlamydiapneumoniae might also
contribute to atherosclerotic plaque formation [18]. This
latter suggestion opens the door to the further complexity
of atherogenesis—a process involving inﬂammatory and
immune responses to a number of targets derived from both
foreign and self antigens.
3.InﬂammatoryMechanisms:
Roles ofEndothelial Cells,Monocytes,
andMacrophages
A mature atherosclerotic plaque contains macrophages, vas-
cular smooth muscle cells laden with lipid, endothelial cells,
and extracellular matrix. The initial pathophysiological step
in atherosclerosis is endothelial injury and monocyte inﬁl-
tration. Endothelial injury manifests itself as increased adhe-
sion molecule expression on the cell surface and cytokine
or chemokine expression and secretion. In atherosclerotic
animal models, vascular cell-adhesion molecule 1 (VCAM-
1) appears in arterial endothelial cells during the initial
vascular response to cholesterol accumulation in the intima.
VCAM-1 expressed in endothelial cells and very late antigen
4 (VLA-4) expressed in leukocytes are important interacting
mediators for leukocytes to inﬁltrate into the subendothe-
lial compartment of the vessel. In addition, the patchy
distribution of adhesion molecules progresses into fatty
streaks. Low-density lipoprotein receptor deﬁcient (Ldlr
−/−)
mice that express a truncated nonfunctional VCAM-1
develop less atherosclerotic plaques [19]. Intercellular adhe-
sion molecule 1 (ICAM-1) is constitutively expressed in
endothelial cells, and its expression increases in the plaque.
However, there are conﬂicting results of ICAM-1 having
proatherosclerotic eﬀects [19, 20]. In addition to integrins,
selectins are also involved in the initial steps of the process.
Apolipoprotein E deﬁcient (ApoE−/−) mice lacking both
endothelial cell selectin (E-selectin) and platelet selectin
(P-selectin) have less severe atherosclerosis [21]. Monocyte
chemoattractant protein 1/Chemokine (C-C motif) ligand
2 (MCP-1/CCL2) and its receptor, CC-chemokine receptor
2 (CCR2), are noted to play an important role in the
initiation of atherosclerosis, probably due to the increased
monocyte and T-cell attraction and inﬁltration into the
plaque. Several studies have demonstrated that oxidized
low-density lipoprotein (oxLDL) is chemoattractant and
that its oxidized phospholipid components can induce
endothelial activation as judged by upregulated expression
of MCP-1 [22, 23]. Other chemokines are also detected in
atherosclerotic plaques, such as the cell-surface anchored
CX3-chemokine ligand 1 (CX3CL1), which is expressed on
vascular smooth muscle cells. MCP-1 is crucial for recruiting
monocytes to atherosclerotic lesions. Crossing ApoE
−/− or
Ldlr
−/− mice with mice lacking MCP-1 or CCR2 leads to
signiﬁcant lesion decrease [24–26]. Many therapeutic drugs
that have anti-atherosclerotic eﬀects may work via their
anti-inﬂammatory eﬀects that speciﬁcally target leukocyte
adhesion and/or chemotaxis. CX3-chemokine receptor 1
(CX3CR1)isexpressedonmonocytesandmacrophages.The
results from the compound deﬁcient mice made by crossing
ApoE
−/− mice with CX3CR1 deﬁcient mice suggest that
CX3CR1 may be involved in monocyte recruitment to the
vessel wall, thereby promoting atherosclerotic plaque for-
mation [27]. These studies all suggest that chemokines and
chemokine receptors are strongly involved in atherogenesis
because they increase monocyte attraction and inﬁltration
into the lesion areas in vessels. Our recent study found that
hyperhomocysteinemia accelerates atherosclerosis by pro-
moting inﬂammatory monocyte diﬀerentiation/macrophage
accumulation in lesions in a new hyperhomocysteinemia
mouse model with an inducible human cystathionine β-
synthase (CBS) transgene in the background of ApoE
−/− and
CBS
−/− compound knock-out (Tg-hCBS/ApoE
−/−/CBS
−/−)
mice fed a high fat diet [17]. Thus it is seen that the risk
factors for atherosclerosis serve to promote any of a number
of inﬂammatory processes involved in the formation or
progression of atherosclerotic plaques.
Vascular cells and inﬁltrated cells have to be activated in
response to stimulation by risk factors for atherosclerosis.
In the last ten years, identiﬁcation of pathogen-associated
molecular patterns (PAMPs) and their receptors (PRRs)
has provided a bridge to link risk factors to initiation of
inﬂammation and secretion of proinﬂammatory cytokines.
Toll-like receptors (TLRs) are a group of PRRs that can
sense a broad range of PAMPs. In addition to TLRs, PRRs
also include Nod-like receptors (NLRs) [28]. The PRRs
may have implications in the development of an anti-
atherosclerotic vaccine for two reasons: (1) they initiate
innate immune responses and inﬂammation by sensing
exogenous and endogenous PAMPs; and (2) they regulate
adaptive immune responses. There may be many TLRs
present in atherosclerotic plaques, mainly on macrophages
and endothelial cells [29]. Crosses of TLR4
−/− and ApoE
−/−
mice show reduced atherosclerosis and altered plaque phe-
notype [30]. Other studies also show that oxLDL and
endogenous heat shock protein 60 (HSP60) can bind to
theTLR4-CD14complexandtriggerinﬂammatoryreactions
with the features of pro-inﬂammatory cytokine secretion
[31, 32], suggesting that PRRs not only recognize exoge-
n o u sP A M P sb u ta l s om a yb ea c t i v a t e db ye n d o g e n o u s
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in the TLR/NLR/inﬂammasome/caspase-1/interleukin (IL)-
1β pathway, our team examined the expression proﬁles of
those genes. Among 11 tissues examined, vascular tissues
and heart express fewer types of TLRs and NLRs than
immune and defense tissues including blood, lymph nodes,
thymus, and trachea. Based on the expression data of
three characterized inﬂammasomes (NALP1, NALP3, and
IPAF), the examined tissues can be classiﬁed into three
tiers: the ﬁrst tier tissues include brain, placenta, blood, and
thymus express inﬂammasome(s) in constitutive status; the
second tier tissues have inﬂammasome(s) in nearly ready
expression status (with the requirement of upregulation of
one component); the third tier tissues, like heart and bone
marrow, require upregulation of at least two components in
order to assemble functional inﬂammasomes. This original
model of three-tier expression of inﬂammasomes would
suggest a new concept of tissues’ inﬂammation privilege and
provides an insight into the diﬀerences among tissues in
initiating acute inﬂammation in response to stimuli. This
model also suggests the possibility that atherogenic risk
factors induce the upregulation of PRRs and inﬂammasome
components to trigger the chronic process of inﬂammatory
atherogenesis [33]. Innate immune system activation is
a critical step in the initiation of an eﬀective adaptive
immune response; therefore, activation of a class of receptors
for PAMPs is a central feature of many adjuvant systems
in vaccine preparations. One member of an intracellular
PRR, the NALP3 inﬂammasome, is activated by a number
of classical adjuvants including aluminum hydroxide and
saponins [34, 35]. Inﬂammasome activation in vitro requires
signaling of both the TLR and NALP3 in antigen-presenting
cells (APCs) [36].
After inﬁltration, monocytes undergo diﬀerentiation
into macrophages, which then become foam cells that
contain a lipid-laden cytosol. Although it is unclear how
these monocytes diﬀerentiate and according to what signal
they diﬀerentiate, scavenger receptors, a group of proteins
that mediate internalization and lysosomal degradation of
lipid, lipopolysaccharide, and apoptotic bodies [37], are
considered to be crucial for lipid accumulation in the
macrophage to ﬁnally form the foam cell. These scavenger
receptors include CD36, CD68, CXCL16, scavenger recep-
tor A (SR-A), SR-B1, and lectin-type oxLDL receptor 1
(LOX1). The internalization and digestion of self and foreign
proteins will facilitate major histocompatibility complex
(MHC) class II antigen presentation [38]. Their MHC II
is directly involved in antigen presentation to CD4+ T-cells
and CD4+ T-cell activation. MHC II is widely expressed or
upregulated in the lesion area on macrophages, endothelial
cells, and smooth muscle cells [39]. This basic function of
macrophages is antigen presentation, which triggers adaptive
immunity and potentially contributes to the autoimmune
character of atherosclerosis. Thus, macrophages are con-
sidered to be professional APCs. Among the internalized
materials, oxLDL is one of the most important contribu-
tors to atherosclerosis and pathologically foam cells laden
with cholesterol and fatty acids are composed of degraded
oxLDL cholesterol ester content. Studies suggest that SR-A
[40], CD36, and CXCL [41] have important functions in
mediatinguptakeofoxLDLandpromotionofatherosclerotic
development.
In addition, MHC class I molecules, which present anti-
genic epitopes to CD8+ T-cells, are constitutively expressed
in macrophages. MHC molecule/antigen epitope complexes
bind T-cell antigen receptors to constitute the ﬁrst signal
in stimulating T-cells, whereas activated macrophages in
lesions also upregulate T-cell costimulation molecules on
the cell surface to form the second signal for T-cell activa-
tion. Presumptive dendritic cells (DCs) bearing the CD11c
integrin and other markers have previously been identiﬁed
in normal mouse and human aorta. DCs are proved to be
particularly abundant in the cardiac valves and aortic sinus.
In all aortic locations, the CD11c+ cells are localized to
the subintimal space with occasional processes probing the
vascular lumen. Aortic DCs express little CD40 but generate
low levels of CD1d, CD80, and CD86. Aortic DCs can cross-
present two diﬀerent protein antigens on MHC class I to
CD8+ TCR transgenic T-cells. In addition, after intravenous
injection, aortic DCs can capture anti-CD11c antibody and
cross-present ovalbumin to T-cells. These results indicate
that bona ﬁde DCs are a constituent of the normal aorta
and cardiac valves [42]. Studies from ApoE
−/− mice also
show the involvement of T-cell costimulation through the
B7s (CD80 and CD86)/CD28 pathway in atherosclerotic
plaques. The other costimulatory factor binding pair, CD40
and CD40 ligand (CD40L), is also widely expressed in the
lesion cells [43]. Inhibition of CD40 signaling, including
genetic disruption of CD40L in ApoE
−/− mice or treating
Ldlr
−/− mice with CD40L antibody, reduces atherosclerotic
lesion formation [44]. Treatment with CD40L antibody also
inhibits the progression of formed plaques and maintains
their stable phenotype [45]. Thus, macrophages are involved
in both innate and adaptive immune responses during
atherosclerosis.
4. AutoimmuneMechanisms:NewT-HelperCell
Subsets, Tregs, andAutoantigens
The discovery that the innate immune system had an active
role in the inﬂammatory process of atherosclerosis was
critical in reinventing the established paradigm [7]. When
it was discovered that the adaptive immune system also had
a signiﬁcantly more complicated role in atherosclerosis—
namely an autoimmune component—the paradigm was
revolutionized yet again [1]. It is now seen that some
immune responses protect against atherosclerosis whereas
others promote it.
Classically, the adaptive immune response follows from
a scenario in which a pathogen escapes elimination by
the innate immune system. The lymphocyte eﬀectors of
the adaptive immune system are activated by interactions
between MHC/antigen complexes, T-/B-cell antigen recep-
tors, and costimulatory molecules on the surface of innate
immune system cells [46]. Professional APCs—dendritic
cells, B-cells, and macrophages—take up, process, and
present antigen epitopes to T-cells, thereby activating them
(Figure 1). B-cell activation requires additional involvement4 Journal of Biomedicine and Biotechnology
of CD4+ T-helper cells (Figure 1). Further, the cytokines
produced during the innate immune response determine the
nature of the adaptive immune response—whether cellular
(T-cell mediated) or humoral (B-cell mediated) [46]. Most
CD4+ T-cells are T-helper (Th) cells, which may be further
classiﬁed on the basis of their induction and the cytokines
that they secrete—an indication of the Th cells’ roles and
eﬀects. For example, interferon-γ (IFN-γ) and IL-12 will
induce activated CD4+ T-cells to become type 1 Th (Th1)
cells that secrete IFN-γ and IL-2 in promotion of cell-
mediated immunity. Similarly, IL-4 will induce activated
CD4+ T-cells to become type 2 Th (Th2) cells that secrete IL-
4,IL-5,IL-10,andIL-13andpromotehumoralimmunityvia
B-cell activation [1, 47]. These two Th subsets further cross-
regulate each other. Subsequent characterization of T-cell
diﬀerentiation has additionally identiﬁed IL-9-producing
and IL-17-producing Th9 cells and Th17 cells subsets,
respectively [48, 49]. Th9 have been observed to enhance
T-cell proliferation while Th17 mediate defenses against
bacteria as well as various autoimmune responses [48, 49].
Most recently, T follicular helper cells (Tfh) have been
identiﬁed as having the unique ability to home to B-cell
follicles where they can induce B-cell antibody production
[50]. In contradistinction to the eﬀectors of the innate
immune response, the eﬀectors of the adaptive immune
response operate with a great deal of speciﬁcity to eliminate
foreign pathogens and generate immunological memory. T-
/B-cell receptors recognize epitopes with great speciﬁcity and
aﬃnity. It has been estimated that there are as many as 1018
B-celland1014 T-cellreceptors[47].Whilethepurposeofthe
adaptive immune response is to eliminate agents containing
antigens perceived as nonself, the scenario in which an
adaptive immune response is mounted against self antigens
does sometimes occur. It is now believed that atherosclerosis
proceeds from such an autoimmune mechanism [12].
Atherosclerotic plaques are seen to contain elements of
both innate and adaptive immunity—mostly macrophages
andT-cellswithfewB-cells[2].Toconﬁrmaroleforadaptive
immunity in atherogenesis, atherosclerotic plaque formation
was observed in T- and B-cell deﬁcient hypercholesterolemic
m i c ea n ds e e nt ob ea t t e n u a t e d[ 51–54]. Further, it was
observed that CD4+ T-cell transfer to these deﬁcient mice
restored lesion formation to that of the control [55]. It was
also noted that atherosclerotic plaques contain numerous
cells producing IFN-γ, IL-12, IL-15, IL-18, and tumor
necrosis factor (TNF) with few in contrast producing IL-
4[ 56–58]. This suggests a role for Th1 cells and not
Th2 cells in promoting atherosclerosis. Further support is
provided by attenuation of atherosclerotic plaque formation
inanimalstudiestargetingmediatorsofT-celldiﬀerentiation
into Th1 cells—for example, IFN-γ, IL-12, IL-18, and TNF
[10, 59–63]. Administration of IFN-γ in order to induce
Th1 diﬀerentiation was seen to increase atherosclerosis in
mice whereas pharmacological inhibition of Th1 cells was
seen to decrease atherosclerosis in these mice [11, 64].
In contrast, Th2 cells seem to mediate anti-atherosclerotic
eﬀects in animal studies. Genetically modiﬁed mice prone
to Th2 immune responses (as opposed to Th1 immune
responses) developed reduced fatty streak formation, which
was reversed by preventing T-cell diﬀerentiation into Th2
cells [65, 66]. Moreover, overexpression of Th2 cytokine
IL-10 in hypercholesterolemic mice reduced lesion size
by 50% [67]. Similarly, Th2 cytokine IL-5 deﬁciency has
been shown to increase atherosclerosis [9]. Nevertheless,
studies with Th2-inducing cytokine IL-4 overexpression
showinconsistentresults[45,68].Thus,Th1cellshaveaclear
proatherogenic role, whereas Th2 cells have a more complex
role in atherosclerosis that is yet to be fully elucidated.
Th1 cytokines are proinﬂammatory and largely promote
atherosclerosis by perpetuating the inﬂammatory mecha-
nisms discussed earlier (Figure 1). IL-12, IL-18, IFN-γ,a n d
TNF, found in atherosclerotic plaques, not only induce
Th1 diﬀerentiation to produce still more cytokines but
also activate macrophages and vascular cells to accelerate
atherosclerosis. IFN-γ activates macrophages and inhibits
endothelial cell and smooth muscle cell proliferation [69,
70]. This produces pro-inﬂammatory cytokines, prothrom-
botic factors, and vasoactive mediators. Meanwhile, TNF
activates the NF-κB pathway in vascular cells to trigger still
more inﬂammation and the generation of reactive oxygen
species,proteolyticenzymes,andprothromboticfactors[71–
73]. These pathways all implicate Th1 adaptive immune
responses in the process of atherosclerosis. On the other
hand, potentially pro-atherosclerotic pathways, associated
with Th2, Th9, Th17, Tfh, and CD8+ T-cells, are not as
well deﬁned [12, 74]. Nevertheless, these cells have obvious
implications in modulating pro- and anti-atherosclerotic
pathways since they diﬀerentiate from a common precursor,
which means that the nuances governing their diﬀeren-
tiation ultimately determine the course of pro- or anti-
atherosclerotic responses. Tfh cells modulate B-cell response
and antibody production (Figure 1); Th2 cells modulate Th1
cell diﬀerentiation and activity; Th17 cells regulate and are
mutually exclusive of immunosuppressive regulatory T-cells
[49, 74]. Further, IL-17 production by Th17 may also play a
role in modulating autoimmune responses in atherosclerosis
(Figure 1)[ 75–77].
CD4+CD25high regulatory T-cells (Tregs) have an impor-
tant role in suppressing both innate and adaptive immune
responses (Figure 1)[ 28]. Our lab among others has shown
that loss of Treg function results in autoimmune responses
[78, 79]. We have characterized a Treg-speciﬁc, IL-2-
dependent apoptotic pathway and demonstrated that Treg
apoptotic/survival pathways are therapeutic targets for Treg-
based immunotherapy. Moreover, we and others have shown
that Treg inhibition accelerates vascular inﬂammation, with
the obvious link to exacerbate atherosclerosis [80–82]. Like
eﬀector T-cells, Tregs require T-cell receptor activation
and costimulation for activation. However, it remains to
distinguish a pathway that exclusively regulates Tregs as
opposed to eﬀector T-cells [83]. Though it was seen that
superagonistic CD28 antibody preferentially activated Tregs
in animal models, phase I clinical trials showed a dangerous
lack of speciﬁcity that triggered a cytokine storm [84–
86]. Nevertheless, direct Treg transplant has proven more
successful [87]. As atherosclerotic plaques contain a depleted
n u m b e ro fT r e g s( 1 % – 5 %o fa l lT - c e l l sv e r s u sn o r m a l l y2 5 %
of all T-cells), this may prove to be a useful strategy forJournal of Biomedicine and Biotechnology 5
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Figure 1: Approaches for vaccine development. This schematic diagram illustrates the adaptive immune response in atherosclerosis (top)
as well as the conventional approach (bottom left) and our proposed bioinformatic approach (bottom right) to vaccine development for
atherosclerosis.
regulation of T-cell dysfunction [88]. It should be cautioned
that excessive T-cell suppression can compromise cellular
defense systems. Ideally, Treg therapy should be targeted to
speciﬁc autoantigens involved in atherogenesis and localized
in atherosclerotic plaques.
In addition to T-cell mediated cellular responses, the
adaptive immune response also includes humoral responses
mediatedbyB-cells.StudieswithT-andB-celldeﬁcientmice
conﬁrmed a net pro-atherogenic role for these mediators
of adaptive immunity [51–54]. However, other studies
demonstrated that splenectomy and consequent loss of some
T- and B-cells led to increased atherosclerosis that could
be reversed by adoptive transfer of B-cells [89–91]. The
primary role of B-cells in atherosclerosis is thought to
consist of antibody production, which may be either pro-
or anti-atherogenic [1, 74]. B-cells can also secrete cytokines6 Journal of Biomedicine and Biotechnology
and serve as APCs, thereby modulating the T-cell adaptive
immune response, though such a role for B-cells has not
been suﬃciently investigated in atherosclerosis. It has been
suggested that a major limitation in appreciating the cellular
responses mediated by B-cells is the failure to appreciate the
existenceofB-cellsubsetsthatcanmediatespeciﬁcresponses
[92, 93]. While speciﬁc B-cell subsets have been identiﬁed in
mice, it still remains to identify them in humans [93]. It is
thought, however, that cells from a B-cell subset termed “B1-
cells”produce“naturalantibodies”oftheIgMsubtypeinaT-
cell and antigen independent manner [94]. Primarily located
in the peritoneal cavity, they provide a ﬁrst line of defense
against foreign pathogens [92, 94]. Intriguingly, IgM natural
antibodies speciﬁc for oxLDL are found in the circulation of
humans without signiﬁcant levels of atherosclerosis [95].
CD4+ T-cells from atherosclerotic plaques have been
shown to have speciﬁcity for oxLDL and HSP60 among
other potential exogenous and endogenous antigens [57, 96–
98]. oxLDL is one of the earliest and best characterized
autoantigens involved in atherogenesis [99]. As an initiating
step in atherogenesis, LDL particles that are trapped within
arterial intima become oxidized and begin to accumulate
as a fatty streak [100–102]. APCs internalize oxLDL via the
scavenger-receptorpathwayand,afterproteolyticprocessing,
bind MHC class II molecules to present peptide fragments
to T-cells [1] .A sT - c e l l sd on o tr e a c tw i t hn a t i v eL D L
components, it is thought that LDL oxidation leads to a
loss of immunogenic tolerance. It has also been suggested
that hypercholesterolemia impairs DC mobility with a
consequent loss of immunogenic tolerance as they are not
able to perform their tolerogenic clearance functions [12,
103–105]. Moreover, the existence of antibodies speciﬁc for
oxLDL particles further indicates that an adaptive immune
response to oxLDL occurs during atherosclerosis [97]. It
has been suggested that the nature of this adaptive immune
responseisacombinationofpathologicalautoimmunityand
protective immunity [12].
HSPs’ expressions are widespread amongst diﬀerent
organisms, and HSPs largely function as chaperones. They
have also been implicated in autoimmune atherosclerosis
[106]. Interest in HSPs as targets, developed from an obser-
vation that Chlamydia pneumoniae have HSPs that are found
in atherosclerotic plaques [18, 107]. Epidemiologically, ele-
vated HSPs have been found in patients with systemic
hypertension, coronary artery disease, carotid atherosclero-
sis, myocardial infarction (MI), and ischemia [107]. Fur-
ther, high levels of antibodies against mycobacterial HSP65
independently predict MI, stroke, and cardiovascular death
[108].TheargumentforHSPsasautoantigensrelatestotheir
cross-reactivity with other bacterial HSPs (e.g., Mycobac-
teria, Chlamydia) and potential recognition by antibodies
against infection by those bacteria [107]. Such autoimmune
recognition has been considered a consequence of a molec-
ular mechanism termed “molecular mimicry” [109]. Other
infectious agents like herpes simplex and cytomegalovirus
have also been found in atherosclerotic lesions [47]. Though
infection is not a necessary contributor to atherosclerosis,
it may certainly play a role in activating PRRs that initiate
innate immune responses leading to subsequent adaptive
immune responses. For example, it has been demonstrated
that TLR9 activation on DCs in atherosclerotic plaques leads
to an autoimmune T-cell attack on vascular smooth muscle
cells [110]. This study demonstrates the mechanism of how
a pathogen can generate a pro-atherogenic autoimmune
response.
5. Vaccine Development for Atherosclerosis
Historically, vaccines have been proved to be a safe and
eﬃcient tool for protection against infectious diseases [111].
Following decades of conceptual and technological break-
throughs, the concept of vaccination has been extended to
a range of diseases not strictly limited to those caused by
infection. Not surprisingly, vaccine design for the treatment
of atherosclerosis has been an actively investigated ﬁeld
for a number of years. Several antigen targets have been
proposed as well as several approaches to vaccine design,
implementation, and eﬃcacy. In some cases this has already
led to funded clinical trials. Vaccines for atherosclerosis are
somewhat diﬀerent from traditional vaccines for infectious
diseases. Ideal vaccines for atherosclerosis should provide
recipients with (1) protective immunity against infection-
derived pro-atherogenic antigens and (2) immune tolerance
for autoimmunogenic self-antigens.
In the previous section, we discussed the immune
responses to pro-atherogenic autoantigens. In this section,
we focus on the research progress using these autoanti-
gens as the targets of vaccine development. As LDL is a
major mediator of atherosclerosis, it is not surprising that
this was the earliest target for anti-atherosclerotic vaccine
therapy [112–116]. These early studies provide conﬂicting,
yet encouraging results. Subsequent studies focusing on
knock-down of oxLDL showed a decrease in atherosclerotic
lesion size [117, 118]. The complexity of LDL has, however,
made identiﬁcation of antigenic epitopes diﬃcult. To this
end, it has been necessary to develop several diﬀerent
experimental models. Early experiments targeted modiﬁed
LDL with some success [119–121]. Still other experiments
targeted components involved in LDL metabolism [122–
124].TargetingoxidizedphospholipidcomponentsofoxLDL
such as phosphatidyl choline (PC) generated enthusiasm in
the ﬁeld since both oxLDL and apoptotic cells express PC
which promotes targeted removal by receptor-scavenger and
IgM pathways [125]. Binder et al. were able to demonstrate
that immunization with PC-containing Streptococcus pneu-
moniae vaccine generated oxLDL-speciﬁc antibodies that
also correlated with reduced atherosclerosis [126]. Caligiuri
et al. further showed that immunization with PC linked to
a carrier protein was suﬃcient to induce speciﬁc antibodies
and signiﬁcantly reduce atherosclerosis [127]. Collectively,
these studies conﬁrm that antibodies against oxLDL epitopes
haveatheroprotectiveeﬀects.Amajorconsiderationremains,
however, as to what potential cross-reactivity will occur
with non-oxLDL endogenous products containing oxidized
phospholipids. For greater oxLDL speciﬁcity, more recent
studies have targeted ApoB-100 peptide fragments following
aldehyde modiﬁcation and proteolytic degradation, whichJournal of Biomedicine and Biotechnology 7
are speciﬁc for LDL [12]. Immunization of mice with
several of these ApoB-100 peptides was seen to reduce
atherosclerosis [128–131].
Studies in animal models have conﬁrmed the potential
antigenicity of HSPs. Xu et al. have demonstrated that
mycobacterial HSP65 elicits a pro-atherogenic immune
response [132, 133]. Based on similar modes of delivery,
other studies corroborate that the immune response against
HSP65 is a pro-atherogenic most likely because of the
innate immune response and Th1 activation [134, 135]. A
diﬀerent strategy using mucosal delivery in order to elicit a
Th2 response showed decreased atherosclerosis [136, 137].
ImmunizationofpatientswithHSP70alsoshoweddecreased
atherosclerosis [138]. Following the idea that molecular
mimicry is the mechanism responsible for human cross-
reactivity with foreign HSPs, vaccination against infectious
agents like inﬂuenza virus has been examined in the context
of atherosclerosis. Though some results are encouraging, the
beneﬁts of the clinical trials have not yet proven convincing
[107, 139]. Similarly, vaccination against hepatitis A was
not seen to change atherosclerotic development in animal
models [140]. Vaccines against still more risk factors for
atherosclerosis have been examined like nicotine [141, 142],
angiotensin I [143], ghrelin [144], and periodontitis [145]
with some interesting results. While all avenues of thought
have serious implications for preventing atherosclerosis, it is
unrealistic to believe that a vaccine constructed from a single
underlying molecular target of a clearly multifaceted disease
process will eﬀectively prevent it. In light of recent advances
in knowledge and technology, it is useful to reevaluate the
delivery and mode of action of vaccines in addition to simply
choosing its targets.
Adjuvants are agents administered along with vaccines
in order to generate an increased immune response to the
vaccine. They often enhance the potency and longevity of
a speciﬁc immune response without themselves inducing
toxicity or initiating long-lasting immune eﬀects [146,
147]. Aluminum salts—aluminum hydroxide, aluminum
phosphate, or simply “Alum”—have been used as adjuvants
since 1926 [148]. In fact, Alum is still used in a number of
US FDA-approved vaccines for diphtheria-pertussis-tetanus,
Haemophilus inﬂuenzae type b, hepatitis B, hepatitis A,
inactivated poliovirus, Streptococcus pneumonia,a n dh u m a n
papilloma virus [146, 149]. Despite its widespread use,
Alum’s mechanism for enhancing immune response has only
recently begun to be understood. Numerous suggestions
abound the following: (1) depot formation facilitating con-
tinuous antigen release, (2) promotion of phagocytosis by
APCs, (3) induction of chemokine secretion by monocytes
and macrophages, (4) inﬂammatory monocyte recruitment,
(5) Th2 persistence and cytokine secretion to facilitate
humoral response, (6) NALP3-dependent caspase-1 activa-
tion with IL-1β secretion [34, 150–154]. Each mechanism
oﬀers a conceivable route by which Alum may enhance
diﬀerent speciﬁc immune responses, though it is not certain
under which circumstances which pathways are activated. A
recent study of Alum in hypercholesterolemic mice showed
thatconditionsofhypercholesterolemiaaﬀectAlum-induced
immune responses. Wigren et al. demonstrated that Alum
inducedTregexpansionandinhibition ofT-cellproliferation
in hypercholesterolemic mice, but not in normal control
littermates [155]. Aside from Treg induction being an
important ﬁnding in its own right, this result points to a very
importantconsiderationinvaccinedesign—properadjuvant
formulation is necessary for eﬃcacy. For more details, Reed
et al. provide an excellent review of adjuvant design and
development [146].
In addition to adjuvants, the route of vaccine delivery
is also important to consider in order to elicit a speciﬁc
immune response. Mucosal (oral or intranasal) immuniza-
tion is often used to induce tolerogenic responses [156].
It is thought that this mode of delivery induces a Th2
mediated response, resulting in Th1 suppression, decreased
inﬂammation, and reduced development of delayed-type
hypersensitivity. Van Puijvelde et al. have shown that orally
administered oxLDL can suppress atherosclerosis via Treg
induction [157]. As an additional consideration, the time
of delivery can also aﬀect the eﬃcacy of the vaccine. The
neonatalimmunesystemisdistinctlydiﬀerentfromtheadult
immune system with a Th2 bias and an abundance of Tregs
[158]. Consequently, it has been shown that immunization
of neonatal mice with oxLDL results in suppressed T-cell
responses to oxLDL and inhibition of atherosclerosis [159].
Thus, while vaccine development for atherosclerosis is
already underway, it’s still important to explore a myriad
of possibilities in order to anticipate future obstacles and
in order to avoid a slow stepwise progression from one
innovation to the next. Identiﬁcation of a single antigen
target is not a suﬃcient end. It would be better to identify
a process that determines how many other targets there may
be and how and when to deliver vaccines against them.
Immunomodulation involves working with the entirety of
the immune system—both innate and adaptive. Determi-
nation of target antigens should be made with the types of
induced immune responses in mind—immunosuppressive
versus immune-provocative, cellular immune responses ver-
sus humoral immune responses, and so forth.
The great availability of databases and bioinformatic
tools characterizing B- and T-cell epitopes allows for eval-
uation of sequences among known autoantigens to identify
suitable epitopes for inducing humoral and/or cellular
immune responses. We previously found that the transcripts
of all the autoantigens involved in various autoimmune
diseases including atherosclerosis are highly modulated by
alternative splicing. In contrast, the RNA transcripts of only
42% ± 5% randomly selected human genes are modulated
by alternative splicing. However, housekeeping splicing of
RNA transcripts could not generate autoantigen epitopes
encoded by alternatively spliced exon(s). The only splicing
events that respond to inﬂammatory/pathological stimu-
lation include extra-exon sequences in mRNA transcripts,
which then generate antigen epitopes previously untolerized
in thymic T-cell development. In support of our observation
via database mining, our experimental reports demonstrated
that (1) the expression of an essential alternative splicing fac-
tor ASF/SF2 is modulated in the autoimmune/inﬂammation
aﬀected tissue in patients with autoimmune disease [160],
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of autoantigens that elicit antitumor immune responses in
patients with tumors [161], and (3) the alternatively spliced
long isoform of unmutated self-tumor antigen CML66 is
immunogenic but not the alternatively spliced short form
of CML66 in patients who developed anti-CML66 immune
responses [162]. Based on these analyses, we proposed a
new “stimulation-responsive splicing” model for generating
untolerized autoantigenic epitopes (see our invited review
for the details) [163]. We propose a similar analysis of
known pro-atherosclerotic antigens in order to determine
ideal autoantigenic epitopes rather than mere guesswork as
to what moieties and modiﬁcations are potentially good
targets. Moreover, by generating a systematic approach to
autoantigen epitope identiﬁcation, we can also lend addi-
tional support in identifying candidate targets hypothesized
by present methods.
6. Bioinformatic Approach for
Vaccine Development
We would like to suggest a bioinformatic approach for
vaccine design that utilizes the vast array of epitope data
available from prediction algorithms and databases. The idea
is to use sequences of known autoantigens to characterize
autoantigenic epitopes recognized by either/both B- and T-
cells. As these recognized autoantigenic epitopes are gener-
ated from experimentally veriﬁed autoantigenic sequences, it
follows that their homology may be characterized. We can
then make statistical comparisons with candidate sequences
to assess their antigenicity. This is a novel approach to
vaccine design as it uses well-characterized information in
order to generate a systematic approach of characterizing
new antigenic candidates. Moreover, this approach has a
structural basis as epitope recognition largely proceeds
from sequence and structure rather than purported pathol-
ogy. Presently, most available vaccines utilize weakened or
inactivated forms of pathogens to either raise neutralizing
antibodiesorstimulatesecondaryimmuneresponsesspeciﬁc
to the antigen of interest (Figure 1)[ 111]. This method of
vaccinology aims to induce immunity similar to that elicited
by natural infections, without the pathogenic autoimmune
consequences. This approach, however, has not been able
to yield eﬀective vaccines for diseases including most types
of cancers, human immunodeﬁciency virus (HIV), tubercu-
losis, and atherosclerosis [166]. To improve the speciﬁcity,
eﬃcacy and safety of traditional vaccines, the concept
of “epitope-based vaccines” was developed, the execution
of which relies on the availability of genomic sequence
databases as well as modern bioinformatic technologies
(Figure 1). Since protein antigens mutate periodically (espe-
cially in viruses implicated in diseases—e.g., inﬂuenza virus,
HIV),itisadvantageoustotargetcommonepitopesequences
that are conserved across subtypes. The identiﬁcation of
conserved genetic variants can be performed using pub-
lic databases such as the NCBI Entrez protein database
(http://www.ncbi.nlm.nih.gov/entrez)[ 163]. Consequently,
a polypeptide that contains genetic information of multiple
epitopes could be engineered to protect against a broad
spectrum of microbial antigenic strains [167]. Utilizing
bioinformatic approaches, combined with biological tools
such as microarray, epitope-based studies of vaccines for
HIV, malaria, and B. meningococcus have produced positive
results [168–170]. Long-term studies in determining the
relationship between antigen structure and antigenicity
havegeneratednumerousantigenicitypredictionalgorithms.
Once the antigenic sequences of interest are identiﬁed, the
predictionandmappingofrelevantT-cellandB-cellepitopes
is the next critical step in the creation of vaccines for
atherosclerosis [107].
B-cells mediate a humoral immune response through
the secretion of antibodies that neutralize invading microbes
and pathogenic antigens. B-cells are stimulated when their
antigen receptors recognize an antigenic epitope, which
could be linear continuous amino acid sequences with about
15 amino acids or discontinuous amino acids connected
via tertiary structures. The conformational aspect of dis-
continuous epitopes complicates the accurate prediction of
B-cell epitopes [164, 171]. The algorithms developed for
the prediction of B-cell epitopes have not been as eﬀective
or accurate [164]. B-cell epitope prediction tools fall into
three categories: prediction based on primary amino acid
sequences, based on conformational structure, and based
on phage-display data. For continuous B-cell epitopes,
prediction algorithms analyze physicochemical properties
of primary sequences including amino acid hydrophilicity,
ﬂexibility, polarity, and turns. Sequence-based tools for the
analysis of continuous B-cell epitopes include ABCprep
[172], Bepipred, BEPITOPE [173], and IEDB B-cell epitope
tools [164]( Table 1). For discontinuous B-cell epitopes,
conformational structures play a more important role in
epitope prediction compared to continuous epitopes, and
structure-based tools have been developed such as Epitopia
[174]a n dE l l i p r o[ 175] for the prediction of continuous
epitopes (Table 1). Programs such as Epitope Mapping Tool
(EMT)andEPIMAPutilizephagelibrariestoscreenepitopes
speciﬁc for known antigens. By analyzing many experi-
mentally identiﬁed antigenic epitopes, we have generated
statistical conﬁdence intervals of antigenicity scores in order
to ascertain the antigenicity of predicted B-cell epitopes
[176]. This may be used to characterize potential vaccine
targets with the aim of inducing a B-cell immune response in
two ways. First, it can be applied to determine if a candidate
antigen can be recognized by B-cells. Also, this method may
be used to generate candidate epitopes within candidate
antigens.
Compared to B-cell epitopes, T-cell epitopes are simple,
short linear 9-15 amino acid sequences. As a result, the
predictiontoolsforT-cellepitopesarebetterdeﬁnedandgive
consistent high-quality results. T-cell epitopes are presented
by MHCs for recognition by speciﬁc T-cell antigen receptors
(TCRs). The interactions between epitopes and MHC as
well as ones between epitope and TCR are critical in
antigen recognition [177]. The binding of epitopes with
MHC is a necessary step in dominant epitope generation
and has been used as a predictor for epitope identiﬁcation.
Epitopes bind to special grooves in MHC molecules, which
consist of speciﬁc sets of amino acids called anchor motifsJournal of Biomedicine and Biotechnology 9
Table 1: B-cell epitope prediction tools. This table, adapted from Table 1 [164] summarizes available websites for B-cell epitope prediction.
The prediction mechanisms employed, URLs, or authors’ email addresses are included. Detailed descriptions and references are included in
the paper.
Name Description URL
ABCpred Based on sequence using recurrent neural network
module http://www.imtech.res.in/raghava/abcpred/
BEPITOPE Based on sequence to predict continuous epitopes jlpellequer@cea.fr
Bepro Based on structure of the antigen to predict
discontinuous B cell epitopes http://pepito.proteomics.ics.uci.edu/
CEP Based on structure for the prediction of continuous
and discontinuous epitopes http://bioinfo.ernet.in/cep.htm
COBEpro
Based on primary sequence of continuous B cell
epitopes. Secondary structure and solvent accessibility
information can be incorporated to improve prediction
http://scratch.proteomics.ics.uci.edu/
DiscoTope Based on sequence and structure for the prediction of
discontinuous epitopes http://www.cbs.dtu.dk/services/DiscoTope/
Ellipro Based on solvent accessibility and protein ﬂexibility http://tools.immuneepitope.org/tools/ElliPro/iedb input
EMT Based on Phage-display for the prediction of
continuous and discontinuous epitopes elro@novozymes.com/
EPIMAP Based on Phage-display for the prediction of
continuous and discontinuous epitopes mumey@cs.montana.edu
Epitopia Based on either protein 3-D structure or linear
sequence using training data http://epitopia.tau.ac.il
IEDB B-cell
epitope tools
Predict continuous B cell epitope based on amino acids
scales and discontinuous epitopes based on 3D
structures
http://tools.immuneepitope.org/main/html/bcell tools
.html
Table 2: T-cell epitope prediction tools. This table, adapted from Table 1 [165], summarizes available websites for T-cell epitope prediction.
The prediction mechanisms employed, URLs, or authors’ email addresses are included. Detailed descriptions and references are included in
the paper.
Name Description URL
BIMAS Half time dissociation to HLA class I molecules http://thr.cit.nih.gov/molbio/hla bind
EpiMatrix Binding eﬃciency with MHC Class I and II http://www.epivax.com/
FRAGPREDICT Binding score of Proteasome Cleavage Sites http://www.mpiib-berlin.mpg.de/MAPPP/cleavage.html
Immune Epitope
Database and Analysis
Resource (IEDB)
Analyze proteasomal processing, TAP transport, and
MHC I&II binding to produce an overall score for a
peptide’s potential for of being a T cell epitope
http://www.immuneepitope.org/
MHCPred Based on MHC/peptide or TAP/peptide IC50
binding values http://www.jenner.ac.uk/
MMBPred Mutated high aﬃnity MHC binding peptides http://www.imtech.res.in/raghava/mmbpred/
NetChop Proteasome or immunoproteasome cleavage sites http://www.cbs.dtu.dk/services/NetChop/
NetCTL Combined scores for MHC subtype binding, TAP
transport and NetChop proteasome scores http://www.cbs.dtu.dk/services/NetCTL/
NetMHC MHC binding propensity of peptides http:/www.cbs.dtu.dk/services/NetMHC
ProPred-1 Eﬃciency of MHC I peptide binding, optional
proteasome/immunoproteasome cleavage ﬁlter http://www.imtech.res.in/raghava/propred1
SYFPEITHI Binding motifs to MHC Class I and II http://www.syfpeithi.com/
TAPPred Binding aﬃnity of TAP proteins http://www.imtech.res.in/raghava/tappred/
TEPITOPE Promiscuous MHC II epitopes http://www.vaccinome.com/
[165]. We found that in addition to the primary anchor
amino acid residues E2 (the second in the epitope) and
E9, some secondary residues including E3, E4, E6, E7, and
E8 as well as some residues in the N-terminal and C-
terminal ﬂanking regions also contribute to binding to MHC
molecule and epitope cleavage [178]. Predictions of epitopes
based on analysis of anchor motif sequences are the most
widely used including SYFPEITHI, BIMAS, and EpiMatrix
(Table 2). The high aﬃnity binding grooves accommodate
peptides in a highly promiscuous manner such that each10 Journal of Biomedicine and Biotechnology
MHC molecule could bind approximately between 1,000
and 10,000 peptide sequences with diﬀerent aﬃnities [179].
Moreover, MHC anchor motif sequences are prone to
mutation and result in polymorphisms. To accommodate
variations, programs such as TEPITOPE (Table 2)h a v eb e e n
created. Furthermore, an assumption underlying prediction
methods analyzing anchor motifs is that each amino acid
residue contributes independently to the overall binding
eﬃciency. In reality, interactions among diﬀerent sites could
inﬂuence the binding property of individual sites [180]. To
address this discrepancy, machine learning methods such
as artiﬁcial neural networks (ANNs) have been devised to
address the complex relationships in the data sets [181].
Epitope-MHC binding is a prerequisite for T-cell epitope
presentation. Generally, the higher the aﬃnity binding is
betweentheantigenic epitope and MHCmolecule,thebetter
the immunogenicity of the epitope. However, epitope-MHC
binding is not the only deﬁnitive epitope indicator. Before
epitope-MHC binding, the peptide needs to be processed
in order to be presented by MHC molecules for T-cell
recognition. This requires two steps: (1) proper protease
cleavage in cytosolic ubiquitin-proteasome-peptidase sys-
tems and (2) translocation from cytosol into endoplasmic
reticulum lumen by the transporter associated with antigen
processing (TAP). Prediction programs such as NetCTL and
IEDB (Table 2) have been designed to account for epitope
proteasome cleavage and TAP binding eﬃciencies.
As with B-cell epitopes, we have generated statistical
conﬁdence intervals of antigenicity scores, proteasome pro-
cessing scores, as well as TAP binding scores for various
tumor antigen epitopes by analyzing many experimentally
identiﬁed antigenic epitopes. This allows us to ascertain the
antigenicity of predicted T-cell epitopes. These statistical
conﬁdence intervals suggest that over 95% of experimentally
identiﬁed antigenic epitopes have the prediction scores
within the intervals [163]. Similar measures could be made
for the design of atherosclerosis vaccines. Proceeding from
experimentally veriﬁed pro-atherosclerotic autoantigens and
mediators will be possible to characterize relevant B- and T-
cell epitopes. Further, candidate antigens may be analyzed
using this result to determine potential antigenicity and
mediation of the desired immune response. The eﬀective
utilization of B-cell and T-cell epitope prediction tools will
greatly save time and eﬀort and enhance future endeavors to
design eﬀective vaccines for atherosclerosis.
7. Discussion
In this review, we have interpolated a number of novel
ﬁndings in the ﬁelds of vascular biology, immunology, and
bioinformatics in order to discuss the development of a vac-
cine against atherosclerosis. We began with a brief discussion
of traditional and novel risk factors for atherosclerosis that
led to the determination of the inﬂammatory components
of atherosclerosis. Now it is seen that the inﬂammatory
pathways of the innate immune response set a course for
an adaptive immune response—speciﬁcally an autoimmune
response—that mediates the progression of atherosclerosis.
Thinking of atherosclerosis in this way makes the disease a
candidate for treatment by vaccine in the traditional sense
of modulating immune responses. However, with recent
technological breakthroughs, vaccine development aﬀords
precision in specifying the nature of the desired immune
response—a useful tool when addressing a disease as com-
plex as atherosclerosis with a manifold of inﬂammatory
and autoimmune components. Moreover, our exploration
of available bioinformatic tools for epitope-based vaccine
design aﬀords a thorough consideration of vaccine design
without expenditure of excess time or resources.
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